GEHC vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GEHC presents a stark contrast between analyst optimism and deterministic fundamental health. The Piotroski F-Score of 3/9 indicates weak financial health, and the current price of $72.91 trades at a significant premium to both the Graham Number ($48.02) and the Intrinsic Value ($31.50). While the company maintains strong ROE (22.38%) and consistent earnings beats, the negative YoY earnings growth (-17.70%) and bearish technical trend suggest a period of instability. The stock is fundamentally overvalued based on deterministic models, though it remains cheaper than the broader healthcare sector average P/E.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GEHC vs LLY: Head-to-Head Comparison
This page compares GE HealthCare Technologies Inc. (GEHC) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.